Sanofi And GSK Initiate P-I/II Study of COVID-19 Protein-Based Vaccine

 Sanofi And GSK Initiate P-I/II Study of COVID-19 Protein-Based Vaccine

Sanofi And GSK Initiate P-I/II Study of COVID-19 Protein Based Vaccine

Shots:

  • The P-I/II will assess the safety, reactogenicity, and immunogenicity of the COVID-19 adjuvanted recombinant protein-based vaccine in 440 healthy adults across 11 sites in the US
  • The companies are expecting the result of P-I/II study in Dec’2020, aiming to initiate P-III study by end of 2020. If clinical data is sufficient, the global companies plan to request regulatory approval in H1’21
  • The preclinical data of the vaccine demonstrated an acceptable reactogenicity profile and high levels of neutralizing antibodies. Additionally, the companies are ramping up manufacturing of the antigen and adjuvant with the target of producing up to 1B doses in 2021

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: Healthcare Radius

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post